CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2006-07-28): Hepatopulmonary syndrome common in patients with hypoxic hepatitis

Clinical

Hepatopulmonary syndrome common in patients with hypoxic hepatitis

Last Updated: 2006-07-28 17:10:26 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Nearly half of patients with hypoxic or ischemic hepatitis suffer from hepatopulmonary syndrome (HPS), with a mortality rate of nearly 50%, Austrian researchers report in the July issue of Gastroenterology.

Hypoxic hepatitis is the leading cause of liver impairment among in-patients, but it hasn't been proven if HPS accompanies hypoxic hepatitis, note Dr. Valentin Fuhrmann and his colleagues at the Medical University Vienna. The team identified 44 patients with hypoxic hepatitis and 62 critically ill patients with cardiopulmonary diseases but without hypoxic hepatitis.

Patient with hypoxic hepatitis were screened for HPS by blood tests, including blood gases, and on contrast-enhanced echocardiography.

Eighteen of the 44 patients with hypoxic hepatitis had elevated serum aspartate transaminase levels and blood gases and echocardiography indicative of HPS. Tests for increased intrapulmonary vasodilation were negative in the other 62 critically ill patients.

"Hepatopulmonary syndrome is reversible after normalization of the hepatic dysfunction in patients with hypoxic hepatitis," Dr. Fuhrmann told Reuters Health. "However, we did not observe complete resolution of hepatopulmonary syndrome with mechanical ventilation."

Dr. Fuhrmann noted that "all critically ill patients with hypoxic hepatitis had severe gas exchange abnormalities due to their underlying disease that caused hepatopulmonary syndrome. However, hepatopulmonary syndrome was not the only cause of respiratory insufficiency in our patients."

"Currently, orthotopic liver transplantation is the only therapy established to reverse intrapulmonary vasodilatation in patients with liver cirrhosis. No randomized controlled trials of pharmacologic therapies are published, but supplemental oxygen improves oxygenation," Dr. Fuhrmann said. "Oxygen should be given to every patient with severe dyspnea associated with hepatopulmonary syndrome."

Gastroenterology 2006;131:69-76.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.